The last time a new class of antibiotics reached the market was nearly three decades ago—but that could soon change, thanks to a discovery by researchers at McMaster University.

A team led by researcher Gerry Wright has identified a strong candidate to challenge even some of the most drug-resistant bacteria on the planet: a new molecule called lariocidin. The findings were published in the journal Nature on March 26, 2025.

The discovery of the all-new class of antibiotics responds to a critical need for new antimicrobial medicines, as bacteria and other microorganisms evolve new ways to withstand existing drugs. This phenomenon is called antimicrobial resistance—or AMR—and it’s one of the top global public health threats, according to the World Health Organization.

From JAMA Cardiol ogy: A centralized, population health coordinator-led notification and clinical support pathway improved the initiation of antihypertensive therapy in patients with left ventricular hypertrophy.

Despite the recognition that poorly controlled hypertension leads to adverse cardiovascular events, there are often barriers in care systems that contribute to substandard recognition and treatment.¹⁹ Notably, prior work employing trained nonphysicians focused on closing gaps in cardiovascular disease management has yielded significant improvements in disease-specific metrics using remote, centralized interventions.^20-25 Similarly, there is a growing body of evidence demonstrating the effectiveness of clinician-directed support systems—often in the form of “nudges”—that have made meaningful advances in a variety of clinical outcomes.^26,27 Whether a methodologic approach combining clinician nudges with the support of trained nonphysicians can be applied to LVH-associated diseases—including hypertension—is unknown.

Accordingly, the NOTIFY-LVH pragmatic randomized clinical trial²⁸ sought to determine whether potentially underutilized echocardiogram data could be leveraged to improve patient care by augmenting the traditional ambulatory care framework. Specifically, this study tested whether a centralized clinical support pathway targeting clinicians of patients with LVH on their prior echocardiograms would increase the rate of treatment for hypertension and the earlier diagnosis of LVH-associated diseases.

Cases of the fungal infection Candida auris are rising rapidly and coming from more sources too, a new US study reveals.

C. auris was first reported in the US in 2016 and is considered an “urgent antimicrobial resistance threat” in hospitals, according to the Centers for Disease Control and Prevention (CDC).

Focusing on a large health system in Miami, Florida, the new research found that reported clinical cases had risen from 5 in 2019 to 115 in 2023 – a considerable jump of 2,200 percent in four years.